Author:
Saeed Dania Khalid,Shakoor Sadia,Razzak Safina Abdul,Hasan Zahra,Sabzwari Saba Faraz,Azizullah Zahida,Kanji Akbar,Nasir Asghar,Shafiq Samreen,Ghanchi Najia Karim,Hasan Rumina
Abstract
AbstractBackgroundMutations in theRv0678,pepQandatpEgenes ofMycobacterium tuberculosis(MTB) have been reported to be associated with reduced antimycobacterial susceptibility to bedaquiline (BDQ). Resistance conferring mutations in treatment naïve MTB strains is likely to have implications for BDQ based new drug regimen that aim to shorten treatment duration. We therefore investigated the genetic basis of resistance to BDQ in MTB clinical isolates from BDQ naïve TB patients from Pakistan. In addition, mutations in genes associated with efflux pumps were investigated as an alternate mechanism of resistance.MethodsBased on convenience sampling, we studied 48 MTB clinical isolates from BDQ naïve TB patients. These isolates (from our strain bank) included 38 MDR/pre-XDR/XDR (10 BDQ resistant, 8 BDQ intermediate and 20 BDQ susceptible) and 10 pan drug susceptible MTB isolates. All strains were subjected to whole genome sequencing and genomes were analysed to identify variants inRv0678, pepQ,atpE, Rv1979c, mmpLS and mmpL5and drug resistance associated efflux pump genes.ResultsOf the BDQ resistant and intermediate strains 44% (8/18) had variants inRv0678including; two reported mutations S63R/G, six previously unreported variants; L40F, R50Q and R107C and three frameshift mutations; G25fs, D64fs and D109fs.Variants in efflux pumps;Rv1273c(G462K),Rv0507c(R426H) andRv1634c(E198R) were found to be present in drug resistant isolates including BDQ resistant and intermediate isolates. E198R in efflux pump geneRv1634cwas the most frequently occurring variant in BDQ resistant and intermediate isolates (n = 10).ConclusionWe found RAVs inRv0678to be commonly associated with BDQ resistance. Further confirmation of the role of variants in efflux pump genes in resistance is required so that they may be incorporated in genome-based diagnostics for drug resistant MTB.
Publisher
Springer Science and Business Media LLC
Subject
Microbiology (medical),Microbiology
Reference63 articles.
1. WHO. Global TB report. Geneva: World Health Organization; 2020. [Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2020]. Last Accessed 4 Februaury 2021.
2. Cholo MC, Mothiba MT, Fourie B, Anderson R. Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. J Antimicrob Chemother. 2017;72(2):338–53.
3. Mbuagbaw L, Guglielmetti L, Hewison C, Bakare N, Bastard M, Caumes E, et al. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis. 2019;25(5):936–43.
4. Tweed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med. 2019;7(12):1048–58.
5. WHO. Technical Manual for drug susceptibility using of medicines used in the treatment of tuberculosis. Geneva: World Health Organization; 2018. [Available from: https://www.who.int/tb/publications/2018/WHO_technical_drug_susceptibility_testing/en/]. Last Accessed 4 Februaury 2021.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献